| Literature DB >> 25356333 |
J Lienard1, A Croxatto1, A Gervaix2, K Posfay-Barbe2, D Baud3, C Kebbi-Beghdadi1, G Greub1.
Abstract
Waddlia chondrophila, an obligate intracellular bacterium of the Chlamydiales order, is considered as an agent of bovine abortion and a likely cause of miscarriage in humans. Its role in respiratory diseases was questioned after the detection of its DNA in clinical samples taken from patients suffering from pneumonia or bronchiolitis. To better define the role of Waddlia in both miscarriage and pneumonia, a tool allowing large-scale serological investigations of Waddlia seropositivity is needed. Therefore, enriched outer membrane proteins of W. chondrophila were used as antigens to develop a specific ELISA. After thorough analytical optimization, the ELISA was validated by comparison with micro-immunofluorescence and it showed a sensitivity above 85% with 100% specificity. The ELISA was subsequently applied to human sera to specify the role of W. chondrophila in pneumonia. Overall, 3.6% of children showed antibody reactivity against W. chondrophila but no significant difference was observed between children with and without pneumonia. Proteomic analyses were then performed using mass spectrometry, highlighting members of the outer membrane protein family as the dominant proteins. The major Waddlia putative immunogenic proteins were identified by immunoblot using positive and negative human sera. The new ELISA represents an efficient tool with high throughput applications. Although no association with pneumonia and Waddlia seropositivity was observed, this ELISA could be used to specify the role of W. chondrophila in miscarriage and in other diseases.Entities:
Keywords: Chlamydia-like organisms; Waddlia chondrophila; intracellular bacteria; mass spectrometry; miscarriage; serology
Year: 2014 PMID: 25356333 PMCID: PMC4184618 DOI: 10.1002/2052-2975.26
Source DB: PubMed Journal: New Microbes New Infect ISSN: 2052-2975
Figure 1Cross-reactivity of the Waddlia chondrophila-specific ELISA. Anti-sera from rabbits (a) or mice (b) immunized with Chlamydia-related bacteria belonging to four different families were used. Cross-reactivity against Protochlamydia amoebophila was tested only with rabbit anti-sera whereas cross-reactivity against Estrella lausannensis and Criblamydia sequanensis was tested only with mouse anti-sera. Note the limited cross-reactivity with other species (open symbols) and the absence of reactivity of the pre-immune sera (in grey).
Comparison of two protocols of the micro-immunofluorescence (MIF) using heat (h-MIF) or formalin (f-MIF) inactivated bacteria applied on 95 sera from British women
| h-MIF | f-MIF | Identical result in both MIF | |
|---|---|---|---|
| Seropositivity | 29 | 57 | 24 |
| Seronegativity | 33 | 14 | 8 |
| Doubtful serology | 33 | 24 | 5 |
| Total | 95 | 95 | 37 |
Figure 2Validation of the ELISA on 95 sera from British women using the reference standard formalin micro-immunofluorescence (f-MIF). OD492nm values of 95 sera from British women tested by ELISA and classified according to the results of the f-MIF. The dashed lines define a grey zone: a low threshold calculated by the receiver operating curve (ROC) to have 100% specificity and the highest sensitivity and a high threshold above OD492nm values corresponding to ‘doubtful low’ sera. Sera with OD492nm values above the grey zone are considered positive. The bars indicate the mean for each group. One representative experiment is shown here.
Figure 3Application of the ELISA to sera from children with (189) and without (175) pneumonia. The dashed lines correspond to the grey zone determined by the receiver operating curve (ROC) (low line) and the doubtful low sera (high line). One representative experiment is shown here.
ELISA applied to sera from children with (n = 189) and without (n = 175) pneumonia
| No pneumonia | Pneumonia | ||||
|---|---|---|---|---|---|
| Only at day 0 | Only at day 14 | At days 0 and 14 | Total | ||
| Negative | 135 (77.1%) | — | — | 149 (78.8%) | 149 (78.8%) |
| Grey zone | 34 (19.4%) | 7 (3.7%) | 2 (1.1%) | 24 (12.7%) | 33 (17.5%) |
| Positive | 6 (3.4%) | 3 (1.6%) | 1 (0.5%) | 3 (1.6%) | 7 (3.7%) |
| Total | 175 | — | — | — | 189 |
The results were obtained from three independent experiments.
Figure 4Sarkosyl insoluble proteins of Waddlia chondrophila identified by mass spectrometry. The 40 most estimated abundant proteins are indicated here. The calculated relative abundance is indicated on the x-axis and illustrates the proportion of each protein in the sarkosyl insoluble protein fraction. Proteins in grey correspond to protein with unidentified function according to the UNIPROT database. The star indicates the proteins with a putative signal peptide in the sequence, ‘Tmd’ corresponds to proteins with a transmembrane domain and ‘Im’ indicates proteins of W. chondrophila previously shown to be immunogenic 12.
Figure 5Two-dimensional (2D) gel of enriched outer membrane proteins from Waddlia chondrophila. The gel is stained with Coomassie blue. After transfer of the 2D gels on nitrocellulose membranes, western blots were performed with human sera previously tested Waddlia negative or positive by the new ELISA. The reactive spots were selected and are numbered here. The reactive spots recognized by Waddlia positive human sera only are indicated by red rectangles.
Results of the western blots performed with human sera previously determined as negative or positive by Waddlia-specific ELISA
| Spots no. | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | ||
| Serum 1 | Negative | ± | + | + | + | |||||||||||||||||
| Serum 2 | + | ± | ± | + | ± | |||||||||||||||||
| Serum 3 | ||||||||||||||||||||||
| Serum 4 | Positive | + | ± | + | + | ± | ± | |||||||||||||||
| Serum 5 | + | + | ± | + | ± | |||||||||||||||||
| Serum 6 | + | + | + | ± | + | |||||||||||||||||
The reactivity of the sera toward 21 spots of proteins is indicated here. Signal intensity in western blot: (+) positive, (±) doubtful, and (−) negative. The spots in bold were analysed by mass spectrometry.
Immunogenic proteins of Waddlia chondrophila identified by mass spectrometry specifically recognized by Waddlia-positive human sera and amino acids sequence identity (%) with other Chlamydiales proteins (BLASTp against a non-redundant database and coverage >60%)
| Spot no. | Protein (gene name) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 | Isocitrate lyase ( | — | — | — | — | — | — | — | — | 64.4 | 68.5 | 71.6 | — | — | — |
| 22 | UDP-4-amino-4-deoxy- | — | — | — | — | — | — | — | — | 52.1 | 52.9 | 56.4 | 53.8 | 58.4 | 30.0 |
| 3,4 | Polyribonucleotide nucleotidyltransferase ( | 62.9 | 62.8 | 62.8 | 59.2 | 62.1 | 61.8 | 62.6 | 59.5 | 66.7 | 67.1 | 70.9 | 68.6 | — | 64.9 |
| 18 | 50S ribosomal protein L1( | 59.0 | 59.4 | 60.7 | 58.1 | 58.1 | 58.1 | 59.0 | 57.2 | 67.0 | 68.5 | 69.7 | 71.9 | 73.3 | 59.4 |
| 19 | 50S ribosomal protein L23 ( | 49.5 | 49.5 | 47.6 | 47.6 | 48.6 | 48.6 | 49.5 | 48.6 | 60.4 | 69.0 | 66.7 | 64.0 | 64.9 | 65.1 |
| 22 | DNA-directed RNA polymerase( | 77.2 | 77.8 | 77.5 | 77.8 | 77.8 | 78.2 | 77.4 | 77.9 | 84.1 | 84.5 | 83.3 | 83.5 | 84.0 | 77.9 |
| 19 | 30S ribosomal protein S8 ( | 51.2 | 52.7 | 53.5 | 51.9 | 52.7 | 51.2 | 51.9 | 51.9 | 65.2 | 60.1 | 66.9 | 71.4 | 71.4 | 55.4 |
| 19 | 30S ribosomal protein S14 ( | 56.4 | 55.5 | 56.4 | 58.4 | 57.4 | 58.4 | 56.4 | 59.4 | 72.3 | 69.3 | 73.3 | 70.3 | 72.3 | 58.4 |
| 4 | Transketolase ( | 56.3 | 56.3 | 56.4 | 56.1 | 58.0 | 56.4 | 56.3 | 55.8 | 67.1 | 68.5 | 68.5 | 68.4 | 69.2 | 64.1 |
| 8 | tRNA modification GTPase ( | 43.5 | 42.5 | 41.6 | 44.6 | 43.4 | 42.8 | 42.3 | 41.6 | 60.7 | 58.2 | 62.5 | 64.7 | 67.0 | 59.1 |
| 18 | Translation elongation factor Ts ( | 44.0 | 43.2 | 42.4 | 44.8 | 44.4 | 43.9 | 43.7 | 41.3 | 58.6 | 57.3 | 65.5 | 61.5 | 61.8 | 51.1 |
| 4 | Periplasmic protease ( | 35.7 | 35.9 | 36.0 | 36.3 | 37.0 | 36.0 | 36.6 | 35.5 | 66.6 | 64.1 | — | 63.3 | 64.6 | 54.6 |
| 8 | Putative uncharacterized protein ( | — | — | — | — | — | — | — | — | 46.0 | 50.1 | 57.6 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||
| — | — | — | — | — | — | — | — | — | — | — | — | ||||
| 22 | Putative uncharacterized protein ( | 33.6 | 33.6 | 34.6 | 33.0 | 29.9 | 32.1 | 32.9 | 33.3 | 42.2 | 42.2 | 49.7 | 44.3 | 43.4 | 36.7 |
| 18 | Putative uncharacterized protein ( | 23.4 | 27.3 | — | — | 22.9 | — | — | — | 59.7 | 59.2 | 59.5 | 55.0 | 59.2 | 48.7 |
| — | — | — | — | — | — | — | — | — | — | ||||||
| 18 | Putative uncharacterized protein ( | 52.6 | 52.6 | 52.2 | 51.3 | 52.6 | 50.9 | 52.6 | 52.6 | 68.9 | 68.7 | 71.1 | 74.9 | 75.7 | 64.1 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |||
| — | — | — | — | — | — | — | — | — | |||||||
| — | — | — | — | — | — | — | — | — | — | — | — | ||||
| 22 | UPF0365 protein* ( | — | — | — | — | — | — | — | — | 79.6 | 79.4 | 78.9 | 74.4 | 75.1 | 67.5 |
In bold: the most promising putative immunogenic proteins for future optimization of the ELISA.